# Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacogenomics-premarket-evaluation-in-early-phase-clinical-studies-and-recommendations-for-labeling/74a84cb7-8271-4fc5-b011-1df725ecf2eb

> FDA guidance document: Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling. Issue date: January 28, 2013. Get complete insights and analysis.

---

## Details

- Title: Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2013-01-28
- Last Changed: 2025-01-31
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2011-D-0082">FDA-2011-D-0082</a>

## Related Documents

- [E3 Structure and Content of Clinical Study Reports - Questions and Answers (R1)](https://www.globalkeysolutions.net/guidances/guidance-document/e3-structure-and-content-of-clinical-study-reports-questions-and-answers-r1/5b7e3d17-9b0a-44df-bfcf-df3fae8991ae)
- [Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets](https://www.globalkeysolutions.net/guidances/guidance-document/best-practices-for-conducting-and-reporting-pharmacoepidemiologic-safety-studies-using-electronic-healthcare-data-sets/5a792e07-313c-4b6e-a098-39e274850db6)
- [Q11 Development and Manufacture of Drug Substances](https://www.globalkeysolutions.net/guidances/guidance-document/q11-development-and-manufacture-of-drug-substances/8d1aacb1-7da4-42f7-9a3a-18b2fc871411)